AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06479317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone oral
Description: Dexamethasone is given at 40mg every morning after meals for 4 consecutive days( if platelet count does not recover higher than 30×10\^9/L after 2 weeks, dexamethasone is given 40mg every day for another consecutive 4 days).
Study NCT06479317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone oral
Description: Dexamethasone is given at 40mg every morning after meals for 4 consecutive days( if platelet count does not recover higher than 30×10\^9/L after 2 weeks, dexamethasone is given 40mg every day for another consecutive 4 days).
Study NCT05986708 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interview
Description: In addition to routine treatment and care, the patients in the application group were interviewed by the researcher once a week for 6 weeks, within the first hour of HD treatment, for a total of 6 sessions, each session being approximately 30 minutes-1 hour, within the scope of the guided self-determination method.
Study NCT05190094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole)
Description: A combination of Palbociclib (125 mg daily per os (3 weeks on-1 week off) with dose adaptation according to safety profile) and non-steroidal aromatase inhibitor (Letrozole (2.5mg ) or Anastrozole (1mg) daily per os).
Study NCT05138939 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Red wine B
Description: 8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.
Study NCT05138939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red wine B
Description: 8 oz (237 ml) of red wine A and red wine B will be blinded and randomized between Japanese Zweigelt red wines from vintages 2015 or 2018.
Study NCT05138939 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: 8 oz (237 ml) of control beverage is a beverage that has similar calories to red wines.
Study NCT05138939 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: 8 oz (237 ml) of control beverage is a beverage that has similar calories to red wines.
Study NCT04233606 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypertonic Saline
Description: Infusion of hypertonic saline to induce an osmotic secretion of the hormone vasopressin
Study NCT04953130 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil® HPV vaccine
Description: Single dose 4-valent HPV vaccine in males. Gardasil®, manufactured by MSD, consists of a licensed prophylactic virus-like particle (VLP) vaccine that protects against 4 HPV genotypes (HPV 6, 11, 16, 18).
Study NCT04953130 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil® HPV vaccine
Description: Single dose 4-valent HPV vaccine in males. Gardasil®, manufactured by MSD, consists of a licensed prophylactic virus-like particle (VLP) vaccine that protects against 4 HPV genotypes (HPV 6, 11, 16, 18).
Study NCT04233606 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Infusion of normal saline to inhibit the secretion of the hormone vasopressin
Study NCT05338190 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Rituximab with subcutaneous belimumab
Description: Belimumab 200 mg subcutaneous weekly (i.e., every 7 days ±1 day) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
Study NCT05338190 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Combination of Rituximab with subcutaneous placebo
Description: Placebo subcutaneous weekly (i.e., every 7 days ±1 day starting from day 0) starting from day 0 through week 24 with 1 g intravenous of Rituximab 7 days and 21 days after the randomization.
Study NCT05213585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin cream
Description: Topical application of ivermectin cream to eyelashes of treatment eye.
Study NCT04701957 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: The Atkins 2: 1 diet as prescribed for the participants of our intervention group (N = 35) is based on a diet moderately rich in protein (meat, fish, cheese, eggs, vegetable proteins) and without restriction of fats, provided they are balanced, but limiting the carbohydrate intake (bread, pasta, rice) to 50 grams / day. The ratio calories from fat / calories from protein + carbohydrates will be 3 to 1
Study NCT04115501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fraction of Inspired Oxygen
Description: Fraction of Inspired Oxygen during cardiac surgery, including cardiopulmonary bypass
Study NCT04780126 — intervention group
Intervention type: OTHER
Intervention: Sarcopenia diagnosis
Description: History, physical, laboratory and ultrasound parameters to diagnose sarcopenia
Study NCT06348160 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iHERO Toolkit Resource
Description: iHERO Toolkit consists of micro-videos and supplemental online resources. Participants will have access to the toolkit housed on pathfactory for 30 days.
Study NCT06559072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: On the basis of routine treatment for aneurysmal subarachnoid hemorrhage, atorvastatin was administered at an ultra early stage at a dose of 40mg/d for 14 consecutive days
Study NCT06561412 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Produce Prescription
Description: Participants will receive either $40 (families of 2 members or less) or $60 (families of more than 2 members) produce vouchers every 2 weeks for 6 months, for a total of $480 or $720. These vouchers are sponsored by The Food Trust.
Study NCT06558838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acyclovir-penciclovir cream
Description: Patients will treat their cold sore with active study drug based upon their randomization
Study NCT06558838 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abreva
Description: Patients will treat their cold sore with Abreva based upon their randomization
Study NCT05705466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Navtemadlin
Description: Navtemadlin is an experimental MDM2 anticancer drug taken by mouth.
Study NCT05705466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Navtemadlin Placebo
Description: Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth.
Study NCT05705466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized antibody used in cancer immunotherapy that will be administered intravenously
Study NCT05705466 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab is a humanized antibody used in cancer immunotherapy that will be administered intravenously
Study NCT02432417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: CQ will start with one week before the start of radiotherapy and end on the last day of radiotherapy.
Study NCT06458452 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Using Virtual Reality based serious gaming module for Advanced Cardiac Life Support
Description: Group VG will use Artificial Intelligence driven Voice Recognition as an interface for game control whereas Group CG will only use hand held Virtual Reality controllers as an interface for game control
Study NCT04991662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metaraminol
Description: Infusion of metaraminol adjusted according to body weight to obtain higher pH value of fetal umbilical artery blood.
Study NCT04991662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Description: Infusion of Phenylephrine adjusted according to body weight to obtain higher pH value of fetal umbilical artery blood.
Study NCT04991662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Infusion of Norepinephrine adjusted according to body weight to obtain higher pH value of fetal umbilical artery blood.
Study NCT05112562 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized attentional bias modification training
Description: In intervention is designed to train participants to disengage attention from potent e-cigarette cues and is based on the well-established attention retraining paradigm for other psychopathologies.
Study NCT05112562 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo attention control training
Description: This control training is very similar to the intervention's overall task structure and stimuli. The only difference is that the this control program is designed to exert no systematic manipulation on the attention deployment pattern between the two stimulus categories, thereby yielding no significant impact on the level of attentional bas toward ENDS-related cues
Study NCT06500117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eMind application
Description: learning phase accompanied by application for 8 weeks, then independent practical application phases
Study NCT06500117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaires
Description: Visual Analogue Scale VAS (craving) and Mobile Application Rating Scale MARS-F
Study NCT06500117 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: focus groupe
Description: Patients who so wish will be able to give us more detailed feedback on the application. The focus groups will be carried out between visit 3 and visit 4.
Study NCT06128304 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core Implementation strategies
Description: Core Implementation Strategies~1. Ongoing consultation~2. Educational meetings~3. Strengthen referral system~4. Prepare patients to be active participants
Study NCT06128304 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core+ Enhanced Implementation Strategies
Description: Includes all of the Core implementation strategies and adds:~5. Community engagement using Health Beginning Initiative Model~6. Smart Cards to facilitate patient engagement
Study NCT06128304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core+ Enhanced Implementation Strategies
Description: Includes all of the Core implementation strategies and adds:~5. Community engagement using Health Beginning Initiative Model~6. Smart Cards to facilitate patient engagement
Study NCT05171192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CMAP Plus LTP
Description: The LTP Plus CMAP intervention will be delivered for a period of 12 weeks, including 8 weekly sessions and 2 sessions fortnightly. First 6 sessions will be for a duration of 60-90 minutes and remaining 4 sessions will take approximately 50-60 minutes. All sessions will be delivered by female therapists trained in CMAP and LTP intervention.
Study NCT06468995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Surveys completion
Description: Completion of surveys: the Feasibility of Implementation Measure (FIM), the Acceptability of Intervention Measure (AIM), the Intervention Appropriateness Measure (IAM), a Likert scale, the EQ-5D-5L questionnaire, the HIV/AIDS-Targeted Quality of Life (HAT-QoL) questionnaire and the HIV Treatment Satisfaction Questionnaire (HIVTSQ).
Study NCT06468995 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surveys completion
Description: Completion of surveys: the Feasibility of Implementation Measure (FIM), the Acceptability of Intervention Measure (AIM), the Intervention Appropriateness Measure (IAM), a Likert scale, the EQ-5D-5L questionnaire, the HIV/AIDS-Targeted Quality of Life (HAT-QoL) questionnaire and the HIV Treatment Satisfaction Questionnaire (HIVTSQ).
Study NCT06468995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Home administration of CAB+RPV
Description: Drug treatment and follow-up at home (home arm).
Study NCT06468995 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hospital administration of CAB+RPV
Description: Drug treatment and follow-up in hospital (hospital arm)
Study NCT04801017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OT-101
Description: TGF β2 specific synthetic 18 mer phosphorothioate antisense oligodeoxynucleotide
Study NCT04801017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemisinin
Description: Herbal Supplement/ Purified extract from Artemisia
Study NCT04801017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Artemisinin
Description: Herbal Supplement/ Purified extract from Artemisia
Study NCT04801017 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride injection
Study NCT05550051 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Awake nasal fiberoptic intubation
Description: Lignocaine nebulization for upper airway block during awake nasal fiberoptic intubation
Study NCT05483946 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Measurement of compartment compressibility
Description: Application of the CPM#1 device for compartment compressibility ratio measurement - for each participant, a pre-defined number of measurements will be conducted per leg and forearm
Study NCT05749081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacidophilin tablets in combination with vonorazan dual therapy
Description: 2400mg lacidophilin tablets three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days
Study NCT05749081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo in combination with vonorazan dual therapy
Description: 2400mg placebo three times daily,1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 10 days
Study NCT05630846 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational MMRV(H)NS vaccine
Description: 1 dose of a measles, mumps, and rubella at release potency and VNS at high (H) potency vaccine administered subcutaneously.
Study NCT05630846 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational MM(H)RVNS vaccine
Description: 1 dose of a measles, rubella, and varicella at release potency and mumps at high (H) potency vaccine administered subcutaneously.
Study NCT06096246 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Description: The catheter ablation (with a CE \[Conformité Européenne\] marked device) is the key specified technique for performing pulmonary vein isolation in the ablation arm in this trial. This allows the physician electrophysiologist to perform a circumferential ablation around the pulmonary veins to electrically isolate the vein, thus preventing pulmonary vein ectopy from triggering AF.
Study NCT06096246 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: DC Cardioversion
Description: DC cardioversion (DCCV) is used to treat irregular heart rhythms (commonly atrial fibrillation). The procedure involves sedation or anaesthetic and placement of electrodes on the chest. An electrical impulse is passed across the electrodes to return the heart rhythm to normal.
Study NCT05630846 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Investigational M(L)M(L)R(L)V(L)NS vaccine
Description: 1 dose of measles, mumps, rubella, and varicella, all at low (L) potency vaccine administered subcutaneously.
Study NCT05630846 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Marketed MMRV_Lot 1 and Lot 2 vaccine
Description: 1 dose of a marketed measles, mumps, rubella, and varicella of Lot 1 or 1 dose of a marketed measles, mumps, rubella, and varicella of Lot 2 vaccine administered subcutaneously.
Study NCT06155201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: functional training
Description: Based on individual differences, children are provided with structural psychological behavioral therapy, including the implementation of aerobic exercise and executive skills training based on motivational quotient theory. Use brain imaging, brain functional imaging and neuromodulation technology to improve children's symptoms.
Study NCT05230056 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PG
Description: Shoulder Digital therapy
Study NCT05230056 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CTRL
Description: Shoulder non-digital therapy
Study NCT05322447 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: L Carnitine ( low dose)
Description: will receive a maintenance dose of L- carnitine 6 gm/day to keep normal level (normal L-carnitine level is normal 25-50 mmol/L)
Study NCT05322447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Carnitine ( high dose)
Description: will receive a high dose of L- Carnitine 18 gm/day as a continuous intravenous infusion to reach double the normal plasma level
Study NCT04696809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teclistamab
Description: Teclistamab will be administered subcutaneously.
Study NCT06096246 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DC Cardioversion
Description: DC cardioversion (DCCV) is used to treat irregular heart rhythms (commonly atrial fibrillation). The procedure involves sedation or anaesthetic and placement of electrodes on the chest. An electrical impulse is passed across the electrodes to return the heart rhythm to normal.
Study NCT06096246 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Implantable loop recorder
Description: The Reveal device is inserted in the pre-pectoral position under the skin. This is performed with local anaesthetic and sedation at least a week before the randomisation. The device will provide a continuous recording of the heart rhythm and rate, and will be able to download duration of AF episodes via a home monitoring system to establish the primary endpoint of the study .
Study NCT06096246 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable loop recorder
Description: The Reveal device is inserted in the pre-pectoral position under the skin. This is performed with local anaesthetic and sedation at least a week before the randomisation. The device will provide a continuous recording of the heart rhythm and rate, and will be able to download duration of AF episodes via a home monitoring system to establish the primary endpoint of the study .
Study NCT06096246 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Femoral sheath insertion
Description: Two femoral sheaths (7Fr) will be inserted using ultrasound guidance under local anaesthetic.
Study NCT06096246 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femoral sheath insertion
Description: Two femoral sheaths (7Fr) will be inserted using ultrasound guidance under local anaesthetic.
Study NCT05649709 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-VA dual therapy
Description: 1000mg amoxicillin capsules twice times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
Study NCT05649709 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: H-VA dual therapy
Description: 1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days
Study NCT06335667 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mpMRI + Diagnostic TURBT
Description: mpMRI in addition to the TURBT surgical procedure
Study NCT06170528 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AURA_ALZ
Description: AURA_ALZ includes the WiFi CSI-based human sensing algorithms, as well as the voice and web interfaces. The devices of AURA_ALZ consists of Fitbit watch, iPad, ASUS routers, Jetson nano, webcam, and Amazon Echo.
Study NCT05419765 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Peripheral blood withdrawn
Description: Peripheral blood will be withdrawn in order to measure haematic lipids (total cholesterol and fractions, triglycerides), total blood LAL activity, to perform genetic analysis and finally to evaluate lipase activity into the platelets.~Hepatic elastography will be also executed, in 100 patients, according to the presence/absence of the PNPLA3 variant, in order to weigh up the genetic predisposition on NAFLD development or progression
Study NCT05884671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulpiride 400 MG
Description: All participants will receive one single dose of 400mg sulpiride. None of the participants will receive repeated doses. In order for the fMRI data acquisition to coincide with the time-window of maximal drug effects represented by a combination of plasma kinetics and physiological effects we will administer the drug 90 minutes prior to fMRI data acquisition.
Study NCT05884671 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All participants will receive placebo during one of the sessions.
Study NCT06155201 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Children with depressive disorders, anxiety disorders, autism spectrum disorders, and attention deficit hyperactivity disorder were recruited at presentation. Differential interventions and assessments were conducted during the study.
Study NCT06023771 — intervention group
Intervention type: PROCEDURE
Intervention: Invasive intervention for acute pancreatitis
Description: Invasive interventions include drainage (endoscopic transmural drainage, imaging-guided percutaneous catheter drainage) and debridement (endoscopic debridement, videoscopic assisted retroperitoneal debridement, laparoscopic surgical debridement, open surgical debridement).
Study NCT06027424 — intervention group
Intervention type: OTHER
Description: observational study, no intervention